Tirzepatide
Dual Agonist. Maximum Results.
What It Treats
How It Works
Tirzepatide activates both GIP and GLP-1 receptors. GLP-1 suppresses appetite and slows gastric emptying. GIP improves fat metabolism and enhances insulin sensitivity in adipose tissue. The dual mechanism produces greater weight loss than GLP-1 alone.
Mechanism of Action
Tirzepatide is the first medication to activate two incretin receptors simultaneously — GLP-1 and GIP. Think of it as a dual-engine approach where semaglutide uses one engine. GLP-1 activation suppresses appetite and slows gastric emptying (same mechanism as semaglutide). But the GIP receptor activation adds something new: it directly improves fat cell metabolism and insulin sensitivity in adipose tissue. The SURMOUNT-1 trial published in the New England Journal of Medicine showed that this dual mechanism produced 22.5% body weight loss at the highest dose — roughly 50% more weight loss than GLP-1 agonists alone. This is why patients who plateau on semaglutide often see renewed progress when switching to tirzepatide.
In 2,539 adults with BMI 30+ (or 27+ with comorbidities), tirzepatide produced dose-dependent weight loss of 15.0% (5mg), 19.5% (10mg), and 22.5% (15mg) vs 3.1% with placebo over 72 weeks. At the highest dose, 62.9% of participants lost at least 20% of their body weight. The study established tirzepatide as the most effective injectable weight loss medication in clinical trials.
Head-to-head comparison of tirzepatide vs semaglutide 1mg in 1,879 patients with type 2 diabetes. Tirzepatide at all doses (5mg, 10mg, 15mg) was superior to semaglutide for both HbA1c reduction and body weight reduction. At 15mg, tirzepatide produced 13.1% weight loss vs 6.7% with semaglutide, while achieving HbA1c below 5.7% (non-diabetic range) in 46% of participants.
The Results
The SURPASS-2 trial, a head-to-head comparison published in the New England Journal of Medicine, showed tirzepatide at all doses was superior to semaglutide 1mg for both weight loss and blood sugar control. At the 15mg dose, participants lost an average of 13.1% body weight vs 6.7% with semaglutide. And the SURMOUNT-3 trial in JAMA demonstrated that patients who first lost weight with intensive lifestyle intervention and then added tirzepatide lost an additional 18.4% beyond their initial loss — proving it amplifies rather than replaces healthy habits.
Adults who first lost at least 5% body weight through 12 weeks of intensive lifestyle intervention then randomized to tirzepatide lost an additional 18.4% body weight (total 26.6%) vs gaining back 2.1% with placebo over 72 weeks. The study demonstrated that tirzepatide dramatically amplifies the effects of behavioral weight loss strategies.
Ideal For
Patients seeking maximum weight loss, those who have plateaued on semaglutide, or individuals with significant insulin resistance or type 2 diabetes alongside obesity.
Your Protocol
Weekly subcutaneous injection. Start at 2.5mg/week for 4 weeks, then 5mg for 4 weeks, with optional titration to 7.5mg, 10mg, 12.5mg, or 15mg based on response and tolerability.
Ready to Start Tirzepatide?
Add to your plan and bundle with other services to save 15%. Or book directly.
Cancellation Policy: A $50 non-refundable deposit is required to confirm your appointment for all consultations — our front desk will reach out to collect it after you book. The deposit is applied toward your visit cost. We require at least 24 hours' notice for cancellations or changes. No-shows or late cancellations will forfeit the deposit. By booking, you agree to these terms.
Business hours: Mon–Thu 8am–6pm · Fri 8am–12pm
